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Background Cardiac resynchronization therapy (CRT) improves outcomes, functional capacity and quality of life in
patients with heart failure. Despite two decades of experience with CRT, the rate of non-response remains approximately 30%.
CRT efficacy is impacted by pacing location, which is anatomically limited in conventional systems. A new wireless
endocardial left ventricular (LV) pacing system allows CRT without such limitations and has shown promise in open-label
studies. The purpose of this study is to evaluate its use in a patient population with poor therapeutic alternatives.
Methods The SOLVE CRT study is an international, multi-center, randomized, double-blind, sham-controlled trial of
patients with Class I and IIa indications for CRT who have either failed to respond to or have been unable to receive
conventional CRT. Enrollment will comprise 350 patients implanted with the wireless CRT system randomized 1:1 to therapy on
(Treatment) or therapy off (Control) for the six-month period over which trial primary endpoints will be evaluated. The primary
safety endpoint will measure the proportion of patients free from system- and procedure-related complications. Primary efficacy
endpoints will assess absolute change in LV end-systolic volume LVESV, proportion of patients reducing LVESV by ≥15% and
clinical composite score for Treatment versus Control patients. Primary endpoints will be evaluated on an intention-to-treat
basis, though per-protocol and as-treated analysis will also be performed.
Conclusion SOLVE-CRT will quantify the safety and effectiveness of wireless CRT in non-responders to conventional CRT
and indicated patients who have been unable to receive CRT via the usual transvenous approach. (AmHeart J 2019;217:13-22.)
Cardiac resynchronization therapy (CRT) is standard-of-
care treatment for patients with mild to severe heart
failure (HF), left ventricular (LV) dysfunction and
interventricular electrical dyssynchrony manifested as
prolonged QRS duration.45 A significant proportion of
patients are non-responsive to CRT due to the anatomical
constraints of the coronary venous anatomy and/or the
limitations of current technology to enable individualized
LV lead placement.1,6-8,10-12,16,18,22,24,28,32,42,44,48 A novel
wireless, endocardial CRT system which overcomes such
issues has recently shown promise in open-label studies
of patients who failed to respond to or who could not be
treated with conventional CRT.4,38 To obtain regulatory
approval in the United States and incorporation into
treatment guidelines, further safety and efficacy evidence
must be developed through a large-scale randomized,
controlled trial. The study design of such a trial is
reported herein.
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Trial Designs
The SOLVE-CRT study
Design and centers
SOLVE-CRT (clinicaltrials.gov identification number
NCT02922036) is a multi-center randomized, double-blind,
sham-controlled evaluationofwirelessCRT in350patients to
be conducted at up to 45 centers in theUnited States, Europe
andAustralia. Up to an additional 90patientsmaybe enrolled
as non-randomized, roll-in patients at sites that do not have
experience implanting the WiSE CRT System. The trial has
been designed in accordance with Good Clinical Practice
standards and conforms to the Declaration of Helsinki.
Regulatory approval has been obtained, as appropriate, from
the competent authority and ethics committee/institutional
review board applicable to each participating center.
Because the system has received CE-Marking and will be
used in accordance with its labeling, competent authority
approval is not required within the European Union.
Patients and background therapies
Study candidates will be required to provide written
informed consent before participating in any study-
related procedure. Patients will be eligible for SOLVE-CRT
if they have a Class I or IIa indication for CRT, based onACC/
AHA/HRS guidelines,17 are on guideline-directed medical
therapy (GDMT) and have either (1) not responded to
conventional CRT for a minimum of 6 months or (2) been
deemed untreatable due to aborted coronary sinus (CS) lead
implantation, disabled pacing from an implanted CS lead or
contraindications for CS lead implant.
Major exclusion criteria include pure right bundle
branch block, excessive LV dilation, unstable/non-
ambulatory NYHA Class IV heart failure, persistent or
permanent atrial arrhythmias, contraindication to antic-
oagulation, short life expectancy, advanced chronic
kidney disease, valvular disease, and recent cardiovascu-
lar/cerebrovascular events. An overview of eligibility
criteria is presented in Table I. A Site Enrollment
Committee at each center will be responsible for
selecting potential patients for inclusion in the study
based on eligibility criteria. An Eligibility Review Com-
mittee, comprised of Heart Failure specialists selected by
the Steering Committee must approve any potential
patients prior to enrollment in the study.
Table I. Condensed Trial Eligibility Criteria.
Inclusion:
1. Class I or IIa indication for CRT-D according to current guidelines:
a. Class I: NYHA II-IV, EF ≤ 35%, LBBB, QRS ≥ 150 ms
b. Class IIa: NYHA II-IV, EF ≤ 35%, LBBB, 130 ≤ QRSb 150 ms
c. Class IIa: NYHA II-IV, EF ≤ 35%, non-LBBB, QRS ≥ 150 ms
2. Patients with a functional CRT system but despite adequate trial of Guideline-Directed Medical Therapy (GDMT) and attempts at optimal device
programming have not responded for ≥6 months, with non-response defined as:
a. EF unchanged or worsened, and
b. Clinical status unchanged or worsened as determined by the Site Enrolment Committee, based on the totality of available clinical evidence (such as
NYHA Class, exercise tolerance, QOL, and/or global assessment)
OR
Patients with a full or partial CRT system deemed ‘previously untreatable’ for one of the following reasons:
a. Patients in whom CS lead implantation has failed
b. CS lead implanted but has been programmed OFF
c. High risk upgrades: relative contraindications to CS lead implant
3. Patient on stable GDMT, in sinus rhythm, age ≥ 18 years and provided written informed consent
Exclusion:
1. Pure RBBB
2. LVEDD ≥8 cm
3. Non-ambulatory or unstable NYHA class IV
4. Contraindication to heparin, chronic anticoagulants or antiplatelet agents
5. Triple anticoagulant patient unable tolerate peri-procedural stopping of anticoagulation therapy
6. Attempted device implant (pacemaker, ICD, CRT, LV lead) or successful co-implant within 1 month
7. Receiving lithotripsy
8. Life expectancy b12 months
9. Undergoing chronic hemodialysis
10. Stage 4 or 5 renal dysfunction evidenced by estimated GFR b30
11. Grade 4 mitral valve regurgitation
12. Implanted noncardiac electrical stimulation therapy device(s)
13. Mechanical aortic or TAVR valve(s)
14. Unstable angina, acute MI, CABG, or PTCA in the last month
15. Correctable valvular disease that is the primary cause of heart failure
16. CVA or TIA within the previous 3 months
17. Persistent/permanent atrial arrhythmia or cardioversion for atrial fibrillation in the past month
18. Moderate or severe aortic stenosis
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All patients must be managed with guideline-directed
medical therapy (GDMT) for HF. This is to include, but is
not necessarily limited to, an aldosterone antagonist, beta-
blocker and one of the following: an angiotensin
converting enzyme inhibitor, an angiotensin receptor
blocker or an angiotensin receptor-neprilysin inhibitor.
Doses of the foregoing medications must be stable for at
least 30 days prior to enrollment with stability defined as
no more than a 100% increase and no more than a 50%
decrease in daily dosage relative to the dose at the
beginning of the 30-day period.
Loading of antiplatelet therapy with clopidogrel and
aspirin is advised for all patients prior to implant.
Intraoperatively during the implant of the Receiver
Electrode, heparin is used to control clotting. Following
the procedure, clopidogrel is recommended for 3 months
and aspirin for the 6-month duration of primary endpoint
data collection. In patients taking direct oral anticoagu-
lants or antithrombin as background therapy, it is
recommended to discontinue therapy 2–3 days before
surgery (or per center practice) and restart after the
implant procedure.
Wireless CRT system
The wireless CRT system (WiSE™ CRT, EBR Systems
Inc., Sunnyvale, CA) has been previously described38 and
is illustrated in Figure 1. Briefly, the system is composed
of an ultrasound pulse generator, a battery, an electrode
with an associated delivery system and a programmer. A
co-implanted cardiac rhythm management device is also
required to provide right ventricular pacing for therapy
and as a trigger for wireless CRT. The ultrasound pulse
generator and battery module are implanted subcutane-
ously. The ultrasound pulse generator is typically
implanted precordially in the 4th to 7th intercostal
space and the battery is placed near the pulse generator
along the mid-axillary line. Since an acoustic window
with line-of-sight to the LV is required for efficient energy
transmission, the pulse generator location is identified
prior to implant using transthoracic echocardiography.
Energy transfer between the pulse generator and the
subsequently-implanted electrode is achieved through a
two-dimensional phased array which enables the trans-
mitter to send a narrow beam of low-intensity ultrasound
directly to the electrode. The electrode converts the
ultrasound that impinges on it into electricity to achieve
stimulation of the endocardium.
Electrode implant is achieved through an interventional
procedure under fluoroscopic guidance. A 12-F, steer-
able, balloon-tipped delivery sheath is introduced by
femoral access and advanced into the LV in retrograde
fashion through the aorta (access to the LV via an atrial
transseptal approach is considered an alternative to the
retrograde transaortic approach based on physician
experience and the patient's risk profile (eg, peripheral
vascular disease)).39Within the sheath is an 8-F delivery
catheter pre-loaded with the electrode. The delivery
sheath is positioned on selected locations of the LV
Figure 1
The wireless CRT system (WiSE-CRT, EBR Systems, Sunnyvale, California) consists of (1) a co-implanted cardiac rhythm management device, (2) a
left ventricular endocardial electrode which receives ultrasound, converts it to electricity and immediately (≤5 ms) paces to administer CRT (3) a
pulse generator module which emits directed ultrasound energy when right ventricular pacing is detected from the co-implant and (4) a battery.
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endocardial surface in the vicinity of the late-activated
region and the electrode tip, which is the pacing cathode,
is positioned near the end of the delivery sheath.
Potential stimulation sites are evaluated for pacing
capture threshold using a standard external stimulation
system connected through the delivery system to the
cathode. Late-activated sites suitable for pacing are
localized using an electrogram measured between the
electrode tip cathode and a reference on the patient.
Preferred sites exhibit maximal latency from onset of the
surface QRS complex to the fist large deflection observed
in the local electrogram (QLV method20,23,26,37,41). When
an optimal pacing location has been identified, the
electrode is affixed to the ventricle by advancing the tip
and its active fixation anchor, under fluoroscopic
guidance, into the endocardium. In a recent study, an
average of 3 positions were tested prior to electrode
fixation and the targeted AHA segment of the heart was
reached 92% of the time (an adjacent segment was
reached in the remainder.)40 The delivery system is then
withdrawn. The fully-deployed electrode is a little larger
than a grain of rice, displacing a volume of 0.05 cc. as
seen in Figure 2. To facilitate endothelialization and
minimize risk of thromboembolism, the electrode is
encapsulated with a woven polyester mesh which has
been observed in animal studies to become fully
endothelialized within 45–60 days.15
Operation of the wireless CRT system is controlled by a
computer-based programmer, which allows selection of
three modes of operation: (1) off, (2) sensing, to assess
that the system is able to accurately detect and
discriminate right ventricular pacing pulses initiated by
the co-implanted cardiac rhythm management system
and (3) synchronous sensing and LV pacing, in which
sensed right ventricular pacing pulses immediately
(within approximately 5 ms) trigger transmission of
ultrasound to the wireless electrode to pace the LV, thus
providing CRT.
Randomization, blinding and follow-up
A block diagram of the trial flow is presented in Figure 3.
Implant of the wireless CRT system will be attempted in all
qualifying patients. Those successfully implanted will be
randomized prior to discharge in equal proportion to the
Treatment and Control groups. Wireless CRT will be
activated in Treatment patients prior to discharge, whereas
Control patients will begin receiving wireless CRT therapy
following completion of endpoint data collection at the 6-
month follow-up visit. Roll-in patients will be programmed
and followed in the same manner as the Treatment group
but will not be included in the endpoint analysis.
All patients will be followed at 1, 3 and 6 months
subsequent to discharge for collection of randomized
endpoint data, culminating in evaluation of primary trial
endpoints when all patients have completed 6 months of
follow-up. Non-blinded data collection will continue
every 6 months thereafter until patients exit the trial.
The time of trial exit is predefined as 24 months for
patients outside the United States, whereas patients
within US will continue to be followed until the system
is approved for commercial release by FDA.
Patients and certain center staff will not be informed of
randomization assignments and will be instructed to
refrain from discussing the topic. Blinded center person-
nel will include those involved in collecting adverse
events and quality of life questionnaires as well as
evaluating patients during physical examination and for
determining NYHA status between the time of random-
ization and completion of 6-month follow-up. Patients
will be unblinded at the end of the 6-month follow-up
visit. A log of blinded personnel will be maintained at
each study site. In the event that a blinded staff member
Figure 2
WiSE CRT System Electrode.
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inadvertently becomes aware of a patient's randomization
assignment, the loss of blinding will be documented and
filed for future reference. Unblinded center personnel
will participate in the randomization process in addition
to echocardiographic examinations and wireless CRT
system device checks during the period between
discharge and 6-month follow-up completion. Aside
from the aforementioned restrictions, all other aspects
of trial data collection may involve blinded and/or
unblinded center staff.
Endpoints
Trial primary endpoints are composed of one primary
safety endpoint and three primary efficacy endpoints
evaluated over the 6-month period of randomized
therapy assignment. All primary endpoints must be
fulfilled for the trial to be deemed successful. The
primary safety endpoint is N70% rate of freedom from
complications caused by a component of the wireless
CRT system or procedure-related vascular events, stroke,
pericardial effusion or pocket events.
The first component of the primary efficacy analysis is a
comparison of change in LV end-systolic volume (LVESV)
between the Treatment and Control arms. It is hypoth-
esized that LVESV will be reduced to a greater extent in
the Treatment arm. The second analysis examines a
potential distribution shift in LVESV. The hypothesis is
that the proportion of patients in the Treatment arm who
Figure 3
SOLVE-CRT study flow diagram.
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experience a reduction in LVESV by 15% or more will be
greater than in the Control arm. The final portion of the
primary efficacy evaluation compares clinical composite
outcomes between the Treatment and Control arms, with
a hypothesis that outcomes among Treatment patients
will be superior to those of Control patients.
Outcomes assessed in the clinical composite outcomes
include NYHA Class, quality of life as measured by the
Kansas City Cardiomyopathy Questionnaire (KCCQ), all-
cause mortality, and HF-related events specified as (1)
unplanned HF hospitalization, (2) emergency department
visit requiring intravenous treatment with diuretics and/
or inotropes to alleviate HF symptoms, (3) unplanned
office visit requiring intravenous diuretic treatment to
alleviate HF symptoms and (4) mechanical assist device
implantation. A patient is deemed worsened if the patient
dies, experiences a HF-related event, increases in NYHA
class or a decrease in KCCQ score of 5 or more points
from baseline. Patient status is improved if not worsened
and NYHA class decreases or KCCQ score increases by 5
or more points from baseline. If not worsened or
improved, the patient status is unchanged.
Two secondary efficacy endpoints evaluate the ability
of the wireless CRT device to achieve and maintain
capture. The first endpoint is intended to demonstrate
that N80% of patients achieve an acoustic energy capture
threshold of 2.9 mJ or less at the post-implant visit,
representing 2:1 safety margin over the maximum
transmitter output of 5.8 mJ. The second endpoint is geared
toward demonstrating that N80% of patients experience a
change in the acoustic energy capture threshold at 6months
of less than 3 times the value at pre-discharge, indicative of
long-term capture threshold stability.
Four tertiary efficacy endpoints further assess the
impact of wireless CRT on measures of HF clinical status
between Treatment and Control arms over 6 months:
mean change in NT-proBNP, proportion of patients with
a change in LV ejection fraction N5%, mean change in
intrinsic QRS duration and proportion of patients who
improve by at least one NYHA Class. Additional pre-
specified ancillary analyses will further explore wireless
CRT device function and the impact of wireless CRT on
HF clinical status.
Statistical considerations
The trial sample size of 350 patients is driven by the need
to power adequately the 3 primary efficacy endpoints. In all
sample size calculations, an attrition rate of 15% is assumed
yielding an evaluable data set of approximately 300 patients.
Change in LVESV between active CRT and sham control
(non-CRT cardiac rhythm management device) has been
estimated in a meta-analysis of 5 trials at 26 mL.25 For
conservative design purposes, a mean difference of 22.5 mL
is assumed for SOLVE-CRT, providing 90% power at a
standard deviation of 60 for a two-sample t-test at a one-sided
alpha level of 0.025.
With respect to relative improvement in LVESV,
previous studies indicate that 55% (range 44%–62%) of
subjects achieve an improvement of at least
15%.6,7,20,23,36,46 In the MADIT-CRT trial,43 the percent-
age change in LVESV among defibrillator patients was
10.2 ± 8.9. Assuming this is a representative mean and
standard deviation and that changes are normally
distributed, the proportion of Control patients in
SOLVE-CRT expected to exhibit a 15% improvement in
LVESV is 32%. With at least a 20% difference between
Treatment and Control arms of LVESV improving by at
least 15%, the planned sample size would provide greater
than 90% power for a one-sided, two-sample binomial test
for differences in proportions at an alpha level of 0.025.
Previous trial results are likewise instructive regarding
expectations for improvement in clinical composite
outcome. In the MIRACLE-ICD trial,49 52.4% of CRT
patients improved compared to 42.9% of defibrillator
patients. Higher rates of CRT patient composite outcome
improvement were observed in other major trials,
ranging from 54–73%.2,11,30,31,49 Based on these results,
the Treatment and Control arm improvement rates are
assumed to be 55% and 40%, respectively. This provides
80% power for a one-sided, two-sample binomial test for
differences in proportions at an alpha level of 0.05. A
higher alpha level is used for this endpoint to maintain
power given the desire to achieve statistical significance
for multiple primary efficacy endpoints.
A survey of previous studies was also used to establish
the primary safety endpoint of system- and procedure-
related complications associated with the wireless CRT
device. The target event-free rate of 77% (lower
confidence bound 70%) was selected by estimating the
aggregate event rate from interventions similar to the
wireless CRT implant procedure, including conventional
CRT device implant, percutaneous coronary intervention,
trans-aortic valve implantation and ablation for ventricu-
lar tachycardia. Relevant events included device dislodge-
ment, pocket complications, vascular complications and
cerebrovascular events. At the planned level of enroll-
ment, the analysis of patients free from events included in
the endpoint is powered at the 85% level with a one-sided
alpha level of 0.05.
For the purposes of fulfilling trial endpoints, all analyses
will be conducted on an intention-to-treat basis. Per-protocol
analyses are also pre-specified in the statistical analysis plan
to enable further insight into treatment effects of active
versus inactive wireless CRT. In addition, an as-treated
analysiswill also be evaluated tomitigate effects of control or
treatment patients prematurely crossing over to the other
treatment group (ie, control to treatment, or treatment to
control). Roll-in patients will be analyzed and reported
separately from the randomized study population.
When analyzing primary and secondary efficacy end-
points, a gatekeeping approach will be applied to control
the Type I error rate. Primary efficacy endpoints will be
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analyzed first. If significant results are obtained, the first
secondary efficacy endpoint will be evaluated and so on
in a hierarchical fashion. If significance is not achieved for
an endpoint, formal testing will conclude and the
remaining endpoints will be summarized using descrip-
tive statistics. No Type I error control will be applied to
the tertiary endpoints.
Missing data will be addressed with multiple imputa-
tion. To understand the effect of missing data on primary
endpoints, tipping point analyses will be conducted that
include all possible combinations of imputed values. Such
an analysis includes the best- and worst-case analyses as
extremes. Primary and secondary endpoint analyses will
also be performed separately for subgroups to assess
consistency of results. Subgroups are defined by baseline
characteristics including sex, race, age, HF severity and
prior treatment history. Consistency of primary efficacy,
primary safety and secondary efficacy outcomes will also
be summarized by geographic region (ie, US vs. non-US).
Poolability will be examined by evaluating the interaction
of study site with endpoint results. Low-enrolling sites
will be grouped for this purpose.
Study administration and timeline
To provide impartial guidance on design and adminis-
tration of SOLVE CRT, the sponsor has chartered an
Eligibility Review Committee, a Steering Committee, a
Clinical Events Committee and a Data Safety and
Monitoring Board. The Eligibility Review Committee
will be comprised of Heart Failure Specialists who will
review appropriate patient enrollment with the individ-
ual Site Enrollment Committees (comprised of an EP and
an HF Specialist at each site). Inclusion/exclusion criteria
will be reviewed along with the patients' GDMT
optimization and stability, and patient life expectancy
will be confirmed to be N12 months. The Steering
Committee, with representation from and support of the
sponsor, is responsible for the trial design, protocol,
statistical analysis plan, publications and overall study
execution. The role of the Clinical Events Committee,
which is blinded to randomization assignment, is to
independently adjudicate adverse events tied to trial
endpoints. The Data Safety and Monitoring Board (DSMB)
will review unblinded safety and efficacy data to ensure
the scientific integrity of the study, safety of current and
future trial participants and effectiveness of the wireless
CRT device. The DSMB will also make recommendations
to the sponsor regarding continuation, modification or
termination of the study based on review of trial results.
With the approval of the Steering Committee, the sponsor
has contracted with independent core laboratories to
analyze echocardiograms, 12-lead electrocardiograms
and 24-hour Holter monitor recordings.
The sponsor will retain monitors to assure data
accuracy and biostatisticians to independently analyze
results according to the statistical analysis plan and other
requests submitted by the various committees. Statistical
analyses will be conducted in SAS version 9.3 or above
(SAS Institute, Cary, N.C.), R version 3.2 or above (R Core
Team, http://www.R-project.org) or another validated
statistical software package.
The SOLVE-CRT study commenced enrollment in the first
quarter of 2018. Accrual of the planned 350 randomized
patients is expected to take 18 to 24 months, resulting in
primary endpoint data becoming available in 2020.
Discussion
Challenges of conventional CRT
Despite two decades of clinical experience with CRT,
the challenge of non-responding patients remains persis-
tent. Approximately 30% of those implanted do not
experience clinical improvement in response to treat-
ment,1,18,32 with estimates of the non-responding popu-
lation ranging from 18% to 45% depending on the
definitions used.18 Reasons for lack of response may
include patient selection,22 myocardial scarring,6,7 LV
lead position42,44 and device programming including
optimization of CRT timing and percentage of time
delivering CRT.16,24
Populations also exist in which CRT has not been a viable
treatment. For example, CS lead implantation fails in a non-
trivial percentage of patients, with failure rates of 7.6% in
MIRACLE,1 5% in CARE-HF12 and in COMPANION10 13% for
CRT-P and 9% for CRT-D. Such failures are often the result of
constraints within the coronary venous anatomy restricting
access to an appropriate LV epicardial pacing site. A further
8–10%11,28 of otherwise eligible patients do not benefit from
CRT as a result of (1) CS leads abandoned due to issues such
as excessive pacing thresholds, phrenic nerve stimulation or
dislodgement and (2) contraindications to CS lead implan-
tation stemming from safety concerns including co-
morbidities, venous occlusion and infections in the pulse
generator pocket.
Patients indicated for, but underserved by, convention-
al CRT could benefit from alternative approaches. While
use of epicardial electrodes placed via thoracotomy has
been an option since the advent of CRT, this option is
infrequently used due to a variety of factors including
procedure invasiveness, lead durability and patient
acceptance. Trans-septal and trans-atrial approaches
have also been proposed for LV lead placement but
have not been widely adopted due to other issues
including the need for long-term anticoagulation.9,33
Thus, there remains a significant unmet need and an
opportunity for new techniques.
Importance of pacing site selection
In evaluating options, the question of optimal pacing
location should be considered. The late-activated region
of the LV has long been recognized as an important target
of resynchronization.13 Short- and long-term outcomes in
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patients paced from the site of latest LV activation are
improved compared to patients with other pacing sites
using a variety of indicators including echocardiography
and hemodynamics.5,20,50 Recent data further suggest
that patient-specific tailoring of LV pacing to the site of
latest activation may improve CRT clinical response.23,26
Interest has also been directed toward endocardial LV
pacing due to its more physiologic depolarization and
repolarization characteristics.19,47 Endocardial pacing
eliminates the inverted pattern of depolarization and
repolarization imposed by epicardial pacing as well as the
attendant increased dispersion of refractoriness which
may elevate risk of proarrhythmia. In practice, acute and
chronic human studies have shown endocardial LV
pacing may improve hemodynamics and clinical out-
comes relative to epicardial pacing, albeit with additional
risk of stroke and TIA associated with leads resident in the
LV.9,33
The WiSE CRT system
Consequently, a clear unmet need exists for the
wireless CRT system under evaluation in SOLVE-CRT.
The small size and pro-endothelialization coating of the
electrode substantially reduce the risk of thromboembol-
ic events. In addition, there are no significant anatomical
barriers to deploying the wireless LV pacing electrode in
the preferred locations. While the system does require a
suitable acoustic window for energy transfer, this posed a
challenge in b8% of patients enrolled in the most
recent trial (clinicaltrials.gov identification number
NCT01905670).38 The open-label evaluation enrolled 35
patients who previously failed to respond to or had
constraints preventing delivery of conventional CRT.
Implantation was successful in 34 patients while 33 met
the study primary endpoint of LV pacing at 1 month, with
31 of 33 patients showing LV pacing at 6 months. System
safety was favorable and meaningfully improved com-
pared to a previous version4 due to the addition of an
atraumatic balloon tip to the endocardial delivery sheath.
Nonetheless, 3 patients experienced perioperative
device- or procedure-related adverse events including
one case of ventricular fibrillation during LV catheteriza-
tion. One acute cerebrovascular accident also occurred in
a patient with atrial fibrillation due to noncompliance
with anticoagulation therapy with no residual neurolog-
ical deficit on recovery. Six months of wireless CRT
resulted in significant improvements LV ejection fraction,
end-diastolic volume (LVEDV), end-systolic volume
(LVESV), intrinsic QRS duration, NYHA Class, and clinical
composite score in the SELECT LV study population.
Importantly, benefits were observed in the majority of
patients despite previous failure or inaccessibility of CRT.
Subsequent to the SELECT LV study, additional patients
have been enrolled as a part of an ongoing Registry
(clinicaltrials.gov identification number: NCT02610673),
which aims to document patient outcomes upon implant,
at 6 months and annually out to 5 years. The most recent
report from this study aimed to evaluate one key
advantage of the small wireless electrode used in the
WiSE CRT System, the ability to target delivery within the
LV. The study showed that, regardless of the technique
used, using targeting methods to determine electrode
placement allowed the investigators to achieve results
superior to those seen in SELECT LV.40
Thus, while safety and performance data accrued to
date are promising and have been sufficient to secure CE-
Marking, a solid evidence basis is required for wireless
CRT to achieve its full potential. The endpoints of SOLVE-
CRT are intended to compellingly address this need.
SOLVE CRT study endpoint rationale
The primary safety endpoint focuses on complications
related to the system and procedures associated with
wireless CRT. By highlighting these adverse events, the
safety profile associated with using the system will be
made clear. Fulfillment of the pre-specified event-free rate
by the system will demonstrate safety parity with
comparable procedures to provide assurance that the
risk level is appropriate in light of anticipated benefits.
The first two primary efficacy endpoints examine the
Treatment versus Control reduction in LVESV and the
difference in proportion of patients reducing LVESV by
15% or more. Reduction in LVESV is a useful marker of
improved LV structure and function, as its value is
reduced both by LV remodeling and by increased LV
ejection. More importantly, reductions in LVESV versus
Control have been shown in previous HF trials to predict
improved patient outcomes.25,43 Concurrent use of the
two endpoints highlights the effects of wireless CRT from
a population as well as an individual patient perspective.
The third efficacy endpoint is a well-known composite of
important clinical outcomes, including objective endpoints
as well as clinician and patient perceptions. Inclusion of this
endpoint provides further assurance that structural/func-
tional improvement is linked with improved outcome. The
secondary efficacy endpoints, which measure pacing
threshold and threshold stability, are important assessments
of long-term feasibility of wireless CRT pacing in the
population as this will characterize the ability to establish
and maintain capture. Finally, tertiary efficacy endpoints
examine other variables frequently assessed in HF with
reduced ejection fraction to provide meaningful compari-
sons with other therapies.
Sham control
As a randomized, double-blinded, sham-controlled trial,
SOLVE-CRT will minimize the impact of placebo and
Hawthorne effects as well as other sources of bias
inherent in open-label studies. Although many of the
elements comprising the endpoints are objective in
nature, recent studies in HF have provided a reminder
that even objective variables may be susceptible to the
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effects of trial participation and a belief that a new
therapy is in effect. Vagus nerve stimulation for HF
provides a case in point: despite promising results from a
single-arm feasibility trial which included significant LV
remodeling14 and other improved biomarkers, a random-
ized, controlled outcomes trial failed to achieve its
primary endpoint despite expanding enrollment based
on interim analysis.21 In contrast, landmark trials of
CRT1,10,12,34,49 have shown improvement in remodeling,
functional capacity, survival and other important markers
for patients with active CRT compared to patients with
cardiac rhythm management devices not delivering CRT
(ie, sham controls).
Limitations
The current embodiment of the WiSE CRT System has
several limitations that may affect the SOLVE CRT Study
as well as clinical use. To begin with, the device requires
the presence and activity of a co-implant device. While all
SOLVE CRT patients would have a co-implant by nature of
their treatment history, this limitation may affect the
extensibility of these results. In addition, the device
requires the availability of an adequate acoustic window
for ultrasound transmission. While this is easily assessed
and yields only an 8% failure rate, the limitation does
affect howmany patients may be treated. Lastly, there are
significant energy losses incurred by the transmission of
power through ultrasound. Though current devices have
an average lifespan of 4.5 years and batteries may be
replaced without pulse generator and electrode replace-
ment, this limitation may lead to additional surgeries for
the patient.
Conclusion
In conclusion the purpose of the SOLVE CRT study is to
evaluate the short and long term safety and efficacy of the
wireless endocardial LV pacing using the WiSE CRT System.
The SOLVE CRT study will provide a thorough and robust
evaluation of this approach. A positive outcome would
demonstrate clinically meaningful improvements in Heart
Failuremay be deliveredwith an acceptable safety profile by
theWiSECRT System. This outcomewould therefore enable
a historically challenging patient population to receive
effective therapy where none exists today.
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